ClinicalTrials.govpublic full text
Efficacy and Safety of PEMbrolizumab PD-L1-positive (>50% of Tumor Cells), Advanced NSCL Cancer(PEMBREIZH)
carcinoma, non-small-cell lung, immunotherapy, pembrolizumab, first line treatment, pdl1 tps > 50%, brain efficacy, observational
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 1045209
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.